Global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals for an enterprise value of approximately $151m.
Marinus is a commercial-stage pharmaceutical company engaged in the development of new therapeutics for seizure disorders.
Go deeper with GlobalData
The agreement will enhance Immedica’s presence in the global rare disease market.
The acquisition process, to be executed through a wholly-owned direct subsidiary of Immedica, will begin with a cash tender offer by Immedica to purchase all issued and outstanding shares of Marinus at $0.55 per share.
As part of the merger deal, Immedica will add Marinus’ZTALMY (ganaxolone) oral suspension, CV. The acquisition is anticipated to speed up Immedica’s revenue growth, adding a commercial-stage asset in the US, with the potential for additional expansion worldwide.
A neuroactive steroid gamma-aminobutyric acid (GABA)-A receptor positive modulator, ZTALMY received approval from the US Food and Drug Administration (FDA) in March 2022.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIt is indicated for treating seizures linked with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients aged two years and above.
Immedica CEO Anders Edvell said: “The acquisition of Marinus represents a transformative step in Immedica’s journey to further strengthen our position as a leading rare disease company.
“By adding ZTALMY to our portfolio, we significantly strengthen our capabilities and expand our presence in the US, marking a new chapter in our mission to deliver impactful therapies for underserved patient populations.”
Furthermore, the deal is poised to expedite Immedica’s growth into the North American market, offering an immediate revenue-generating product and a commercial team.
The board of directors of Marinus have unanimously approved the merger and recommended that stockholders tender their shares in the offer.
Subject to customary conditions and approvals, the transaction is anticipated to be conclude in the first quarter of 2025.
Headquartered in Stockholm, Sweden, Immedica is backed by the investment companies KKR and Impilo. The company is focused on the commercialisation of medicines for rare diseases and specialty care products.
Immedica employs about 130 people across Europe, the Middle East and the US.
